EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Real-world experience with cefepime/zidebactam under compassionate use

Dilip K Dubey, Subramanian Swaminathan, Praveen K Tirlangi, Vishnu Rao Polati, Rajeev Soman, Rasika Sirsat, Abdul Ghafur, Raman Gaikwad, Vasant Nagvekar, Abi S Manesh, Irfana Mohammed, Harshad S Limaye, Pooja H Shah, Ankit Mittal, Pratik Y Patil, Nitin Gupta, Umang Agrawal, Manish Soneja, Sowmya Sridharan, Surabhi Madan, Sandeep K Mitra, Monalisa Sahu, Ayesha J Sunavala, Kedar K Toraskar, Tanu Singhal, Ashwini R Tayade, Neha Gupta, Anjely P Sebastian, Vijil Rahulan, Suneetha Narreddy, Erlinda R Ulloa, William R Miller, Vidya Krishna, Honey S Savla, Radhika N Sarda, Nitin Bansal, Shalmali B Inamdar, Harshith B Kadnur, Siddhant Shetty, Vikas Deswal

Journal of Antimicrobial Chemotherapy · 2026-11-03 · 81 (12)

DOI: 10.1093/jac/dkag324 ↗
AbstractBibliografische Angaben

Abstract

Abstract Introduction Cefepime/zidebactam is a β-lactam/β-lactam enhancer combination with activity against carbapenem-resistant (CR) Gram-negative pathogens, including metallo-β-lactamase (MBL)-producing organisms. Before regulatory approval, cefepime/zidebactam was available through a compassionate-use programme for patients with CR Gram-negative infections who had limited available treatment options. Methods We conducted a retrospective, multi-country analysis of patients who received cefepime/zidebactam through compassionate use between 2022 and 2025. Data included demographics, comorbidities, acute complications, prior antibiotic exposure, infection characteristics, microbiology, treatment details, and investigator-assessed outcomes. Results Eighty-five patients were included (median age 48 years; 57.6% in an intensive care unit at initiation). Primary infections included pneumonia/respiratory infection (30.6%), bone and joint infection (24.7%), and complicated urinary tract infection/pyelonephritis (14.1%). Pseudomonas aeruginosa was the predominant pathogen (77.6%), followed by Klebsiella pneumoniae (14.1%) and Acinetobacter baumannii (11.8%); infections involving at least two Gram-negative pathogens occurred in 10.6%. Among isolates with available genotypic data, MBLs were common and predominantly NDM. The cefepime/zidebactam minimum inhibitory concentration (MIC)50 and MIC90 were 8 and 32 mg/L, respectively. Investigator-assessed clinical success at the end of therapy was achieved in 88.2% of patients (95% CI, 79.7–93.5), and microbiological eradication in 89.4% (95% CI, 81.1–94.3); on-therapy mortality was 10.6% (95% CI, 5.7–18.9). Treatment-emergent adverse events occurred in five patients (5.9%, 95% CI, 2.5–13.0), with one discontinuation. Conclusions In this uncontrolled compassionate-use case series, cefepime/zidebactam treatment was accompanied by high investigator-assessed clinical success and microbiological eradication in patients with severe infections caused by CR Gram-negative pathogens. These observations require confirmation in prospective controlled studies.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →